Posts by author
Yeva Margaryan
Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
Personalised neoantigen cancer vaccines (both with and without ipilimumab) elicited anticancer immune responses in nine patients with fully resected clear cell renal cell carcinoma. The investigator-initiated phase 1 trial, published in Nature, February 5 2025, observed no recurrences at a…
What Caught Our Eye in April: Oncology’s Top Moments
April 2025 marked a significant month in oncology, with notable advancements in cancer treatment and research. Here’s a summary of the most compelling studies and recent breakthroughs that caught our eye this month. Popular CT scans could account for 5%…
Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
Every year, the Sjöberg Prize, established by the Royal Swedish Academy of Sciences, honors researchers whose scientific discoveries in oncology are reshaping the understanding and treatment of cancer. The award stands alongside the most prestigious accolades in science, not only…
CancerWorld #102 (April 2025)
The People Behind the Progress in Oncology is science. But it is also stories. It is policy. It is power. It is knowledge. It is culture. It is trust. And above all, it’s personal. This is the lens through which…
What Caught Our Eye in March: Oncology’s Top Moments
March saw the publication of several important studies in oncology, shedding new light on cancer treatment and care. Here’s a roundup of the key studies on recent discoveries and breakthroughs that grabbed our attention this month. Small device, big impact:…
CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs
After transitioning to a fully digital format in 2022, CancerWorld is making a highly anticipated return to print with its February 2025 issue. This edition delivers in-depth analysis, expert perspectives, and the latest advancements in cancer research, policy, and treatment.…